PTC Therapeutics announced the completion of their rolling submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA) for Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).  

The FDA has previously granted Translarna Orphan Drug status for DMD, cystic fibrosis (CF), Mucopolysaccharidosis I (MPS I), and aniridia.

RELATED: FDA Grants Orphan Drug Designation to new Treatment for Duchenne Muscular Dysptrophy (DMD)

Translarna is an investigational, first-in-class, oral protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation such as in nmDMD.

For more information visit